Dr. Prateek Mendiratta, MD

Dr. Mendiratta practices at University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System.

Dr. Mendiratta's NPI, 1104960525, was assigned on February 18, 2007. Dr. Mendiratta holds Ohio license 35.097580.

Dr. Mendiratta's primary practice is University Hospitals Cleveland Medical Center, at 11100 Euclid Avenue, Cleveland, OH 44106 in Cuyahoga County. The practice phone is (216) 844-1000.

Dr. Mendiratta's primary practice is University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System. Dr. Mendiratta is also affiliated with University Hospitals TriPoint Medical Center. The medical group on file is University Hospitals Medical Practices. Dmand AI also links Dr. Mendiratta to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mendiratta practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Mendiratta's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Mendiratta's licenses on file in 2 states: Ohio and South Carolina.

CMS data shows 659 Medicare services from Dr. Mendiratta across 8 procedure codes in 2024, for 218 Medicare patients. Medicare paid $44,174 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 218 Medicare patients who saw Dr. Mendiratta in 2024. The largest group is 75 to 84, with 93 patients. 75% of them have cancer, and 75% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mendiratta's median patient age at 74, with 19% women.

In 2024, Dr. Mendiratta wrote 1,236 Medicare Part D claims for 177 patients. 70% of them were for generic drugs. CMS names the drug for 1,113 of them, across 23 drugs with 11 or more claims each, at $4,524,498 in total drug cost. In 2023, CMS named 927 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Mendiratta for performance year 2024, reported as part of a group. Dr. Mendiratta accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mendiratta as offering telehealth.

Dmand AI links 20 papers to Dr. Mendiratta, published from 2017 to 2024. 2018 was the busiest year, with 6. The most frequent topics are Antineoplastic Agents, Carcinoma, Renal Cell and Disease Progression. Dr. Mendiratta has published most often in Target Oncol. Dr. Mendiratta's most frequent co-authors are Petros Grivas, MD, Matthew M. Cooney, MD and Hamid Emamekhoo, MD.

Dmand AI links Dr. Mendiratta to 6 clinical trials, 2 of them phase 2/3 studies. 5 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Carcinoma, Renal Cell. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 343 general payments to Dr. Mendiratta from 31 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 74% of the total. Seagen Inc. paid the most, $111,576.